Taxus Free: Angiotech Carves Out New $625 Million Subsidiary
This article was originally published in The Gray Sheet
Executive Summary
Combo product firm Angiotech Pharmaceuticals' creation of a new investor-supported subsidiary for its non-paclitaxel business could lead to an eventual spinoff of Angiotech Pharmaceutical Interventions, the firm announces July 7
You may also be interested in...
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Abbott remains confident that it will gain 25% to 30% share of the U.S. drug-eluting stent market over the next year now that it has launched its Xience V everolimus-eluting stent
Angiotech Seeks Partner For Stalled Vascular Wrap R&D Program
Combination product developer Angiotech is looking for someone to help fund its stalled drug-eluting Vascular Wrap R&D program as part of a broader effort to return to profitability by year-end
With AMI Buy, Angiotech Looks To Become Less Reliant On Partnerships
Angiotech Pharmaceuticals' $785 mil. acquisition of American Medical Instruments Holdings will allow the firm to diversify its revenue stream and retain more control over its combination product business